RNA Relative Valuation
RNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNA is overvalued; if below, it's undervalued.
Historical Valuation
Avidity Biosciences Inc (RNA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.41. The fair price of Avidity Biosciences Inc (RNA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：71.54
Fair
-13.62
PE
1Y
3Y
5Y
Trailing
Forward
-12.11
EV/EBITDA
Avidity Biosciences Inc. (RNA) has a current EV/EBITDA of -12.11. The 5-year average EV/EBITDA is -4.48. The thresholds are as follows: Strongly Undervalued below -10.97, Undervalued between -10.97 and -7.72, Fairly Valued between -1.23 and -7.72, Overvalued between -1.23 and 2.02, and Strongly Overvalued above 2.02. The current Forward EV/EBITDA of -12.11 falls within the Strongly Undervalued range.
-11.59
EV/EBIT
Avidity Biosciences Inc. (RNA) has a current EV/EBIT of -11.59. The 5-year average EV/EBIT is -4.54. The thresholds are as follows: Strongly Undervalued below -11.26, Undervalued between -11.26 and -7.90, Fairly Valued between -1.18 and -7.90, Overvalued between -1.18 and 2.18, and Strongly Overvalued above 2.18. The current Forward EV/EBIT of -11.59 falls within the Strongly Undervalued range.
951.83
PS
Avidity Biosciences Inc. (RNA) has a current PS of 951.83. The 5-year average PS is 230.36. The thresholds are as follows: Strongly Undervalued below -209.02, Undervalued between -209.02 and 10.67, Fairly Valued between 450.05 and 10.67, Overvalued between 450.05 and 669.74, and Strongly Overvalued above 669.74. The current Forward PS of 951.83 falls within the Strongly Overvalued range.
-23.51
P/OCF
Avidity Biosciences Inc. (RNA) has a current P/OCF of -23.51. The 5-year average P/OCF is -10.37. The thresholds are as follows: Strongly Undervalued below -22.78, Undervalued between -22.78 and -16.58, Fairly Valued between -4.17 and -16.58, Overvalued between -4.17 and 2.04, and Strongly Overvalued above 2.04. The current Forward P/OCF of -23.51 falls within the Strongly Undervalued range.
-20.07
P/FCF
Avidity Biosciences Inc. (RNA) has a current P/FCF of -20.07. The 5-year average P/FCF is -8.54. The thresholds are as follows: Strongly Undervalued below -18.42, Undervalued between -18.42 and -13.48, Fairly Valued between -3.61 and -13.48, Overvalued between -3.61 and 1.33, and Strongly Overvalued above 1.33. The current Forward P/FCF of -20.07 falls within the Strongly Undervalued range.
Avidity Biosciences Inc (RNA) has a current Price-to-Book (P/B) ratio of 5.57. Compared to its 3-year average P/B ratio of 2.75 , the current P/B ratio is approximately 102.66% higher. Relative to its 5-year average P/B ratio of 2.71, the current P/B ratio is about 105.45% higher. Avidity Biosciences Inc (RNA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -12.68%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.53% , the current FCF yield is about -100.00% lower.
5.57
P/B
Median3y
2.75
Median5y
2.71
-5.49
FCF Yield
Median3y
-12.68
Median5y
-11.53
Competitors Valuation Multiple
The average P/S ratio for RNA's competitors is , providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 434.03%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RNA increased by 146.01% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.34M to 12.48M.
The secondary factor is the Margin Expansion, contributed -59.37%to the performance.
Overall, the performance of RNA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Avidity Biosciences Inc (RNA) currently overvalued or undervalued?
What is Avidity Biosciences Inc (RNA) fair value?
How does RNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Avidity Biosciences Inc (RNA) as of Dec 05 2025?
What is the current FCF Yield for Avidity Biosciences Inc (RNA) as of Dec 05 2025?
What is the current Forward P/E ratio for Avidity Biosciences Inc (RNA) as of Dec 05 2025?